Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 28 Oct 2015
At a glance
- Drugs Tasquinimod (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Active Biotech Research
- 31 Aug 2018 Biomarkers information updated
- 03 Jun 2013 Retrospective follow-up data was presented at the 2013 ASCO Annual Meeting, according to an Active Biotech media release.
- 16 May 2013 Data will be presented at the 2013 ASCO Annual Meeting, according to an Active Biotech media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History